Anaemia and Long Term Mortality in Heart Failure Patients: A Retrospective Study
暂无分享,去创建一个
L. Køber | P. Weeke | C. Torp-Pedersen | N. Valeur | M. Charlot | M. Seibæk
[1] P. Ponikowski,et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. , 2007, Journal of the American College of Cardiology.
[2] J. McMurray,et al. Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial , 2007, European journal of heart failure.
[3] J. McMurray,et al. Anemia and Its Relationship to Clinical Outcome in Heart Failure , 2004, Circulation.
[4] A. Go,et al. Hemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study , 2006, Circulation.
[5] M. Kruszewski,et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. , 2008, European heart journal.
[6] M. H. Gault,et al. Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.
[7] G. Filippatos,et al. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 2008, American heart journal.
[8] L. Køber,et al. An echocardiographic method for selecting high risk patients shortly after acute myocardial infarction, for inclusion in multi-centre studies (as used in the TRACE study). TRAndolapril Cardiac Evaluation. , 1994, European heart journal.
[9] A. Besarab,et al. Managing anemia in patients with chronic heart failure: what do we know? , 2010, Vascular health and risk management.
[10] Anil K. Jain,et al. Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. , 2008, Journal of the American College of Cardiology.
[11] I. Shapira,et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. , 2001, Journal of the American College of Cardiology.
[12] C. Lang,et al. Effect of Erythropoietin on Exercise Capacity in Patients With Moderate to Severe Chronic Heart Failure , 2003, Circulation.
[13] H. Hillege,et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. , 2008, Journal of the American College of Cardiology.
[14] L. Tavazzi,et al. Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. , 2005, Journal of cardiac failure.
[15] P. Ponikowski,et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa on hemoglobin response and symptoms in patients with heart failure and anemia , 2006 .
[16] I. Shapira,et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. , 2000, Journal of the American College of Cardiology.
[17] M. Mosller. Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: Rationale, design, and patient characteristics of the DIAMOND studies , 1997, Clinical cardiology.
[18] S. Solomon,et al. Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF)™ Trial , 2006 .